2012598-91-1
2012598-91-1
Chemical Structure
Rufinamide-15N,d2-1
Synonym(s): CGP 33101-15N,d2-1; E 2080-15N,d2-1; RUF 331-15N,d2-1
- CAS No.: 2012598-91-1
- Formula:C10H6D2F2N315NO
- Molecular Weight:241.20
InChIKey: POGQSBRIGCQNEG-QGIRLOETSA-N
SMILES: O=C(C1=C[15N](C([2H])([2H])C2=C(F)C=CC=C2F)N=N1)N
Biological Activity: Rufinamide-15N,d2-1 (CGP 33101-15N,d2-1) is 15N- and deuterium-labeled Rufinamide (HY-A0042).Rufinamide (CGP 33101) is an orally active antiepileptic compound that inhibits Na+ current activation, inhibits neuronal hyperexcitability, and has anticonvulsant effects. Rufinamide is used in the study of Lennox-Gastaut syndrome[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Rufinamide-15N,d2-1 | Rufinamide-15N,d2-1 (CGP 33101-15N,d2-1) is 15N- and deuterium-labeled Rufinamide (HY-A0042).Rufinamide (CGP 33101) is an orally active antiepileptic compound that inhibits Na+ current activation, inhibits neuronal hyperexcitability, and has anticonvulsant effects. Rufinamide is used in the study of Lennox-Gastaut syndrome. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Rufinamide (Standard) | ≥98% | Rufinamide (Standard) is the analytical standard of Rufinamide (HY-A0042). This product is intended for research and analytical applications. Rufinamide (CGP 33101) is an orally active antiepileptic compound that inhibits Na+ current activation, inhibits neuronal hyperexcitability, and has anticonvulsant effects. Rufinamide is used in the study of Lennox-Gastaut syndrome. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Rufinamide-d2 | Rufinamide-d2 (CGP 33101-d2) is the deuterium labeled Rufinamide (HY-A0042). Rufinamide (CGP 33101) is an orally active antiepileptic compound that inhibits Na+ current activation, inhibits neuronal hyperexcitability, and has anticonvulsant effects. Rufinamide is used in the study of Lennox-Gastaut syndrome. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Rufinamide-15N,d2 | Rufinamide-15N,d2 (CGP 33101-15N,d2) is the deuterium and 15N labeled Rufinamide (HY-A0042).Rufinamide (CGP 33101) is an orally active antiepileptic compound that inhibits Na+ current activation, inhibits neuronal hyperexcitability, and has anticonvulsant effects. Rufinamide is used in the study of Lennox-Gastaut syndrome. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Rufinamide | 99.88% | Rufinamide (CGP 33101) is an orally active antiepileptic compound that inhibits Na+ current activation, inhibits neuronal hyperexcitability, and has anticonvulsant effects. Rufinamide is used in the study of Lennox-Gastaut syndrome. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Chen JL, et.al. Inhibition of resurgent Na+ currents by rufinamide. Neuropharmacology. 2024 Apr 1;247:109835. [Content Brief]
- [3]. White HS, et.al. The anticonvulsant profile of rufinamide (CGP 33101) in rodent seizure models. Epilepsia. 2008 Jul;49(7):1213-20. [Content Brief]
- [4]. Suter MR, et.al. Rufinamide attenuates mechanical allodynia in a model of neuropathic pain in the mouse and stabilizes voltage-gated sodium channel inactivated state. Anesthesiology. 2013 Jan;118(1):160-72. [Content Brief]
